Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Tetsunari Hase"'
Autor:
Takahiro Hatta, Tetsunari Hase, Toru Hara, Tomoki Kimura, Eiji Kojima, Takashi Abe, Yoshitsugu Horio, Yasuhiro Goto, Naoya Ozawa, Naoyuki Yogo, Hirofumi Shibata, Tomoya Shimokata, Tetsuya Oguri, Masashi Yamamoto, Kiyoshi Yanagisawa, Masahiko Ando, Yuichi Ando, Masashi Kondo, Makoto Ishii, Yoshinori Hasegawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15955-15969 (2023)
Abstract Background The Cockcroft–Gault formula is commonly used as a substitute for glomerular filtration rate (GFR) in Calvert's formula for carboplatin dosing, where adjusting serum creatinine measured using the enzymatic method with 0.2 mg/dL h
Externí odkaz:
https://doaj.org/article/a40d3403fb414a989bb00b6f8030a3d5
Autor:
Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, Kenji Chibana, Kyoichi Kaira, Kyoichi Okishio, Eiki Ichihara, Shuji Murakami, Mototsugu Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: ALK-tyrosine kinase inhibitors (ALK-TKIs) are effective for treating non-small-cell lung cancer with ALK gene rearrangement; however, resistance is inevitable. Brigatinib is a unique ALK-TKI that is effective against many resistance mutat
Externí odkaz:
https://doaj.org/article/49d4fe358af74383a12fd7f0ddcc1676
Autor:
Hiromasa Tanaka, Daijiro Iwata, Yuki Shibata, Tetsunari Hase, Daisuke Onoshima, Naoyuki Yogo, Hirofumi Shibata, Mitsuo Sato, Kenji Ishikawa, Ikuo Nagasawa, Yoshinori Hasegawa, Makoto Ishii, Yoshinobu Baba, Masaru Hori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Various liquid biopsy methods have been developed for the non-invasive and early detection of diseases. In particular, the detection of circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs) in blood has been receiving a gre
Externí odkaz:
https://doaj.org/article/691b5df5199a459b98fac9e5ddf5e7bd
Autor:
Mei-Chee Tai, Leonidas E. Bantis, Gargy Parhy, Taketo Kato, Ichidai Tanaka, Chi-Wan Chow, Junya Fujimoto, Carmen Behrens, Tetsunari Hase, Koji Kawaguchi, Johannes F. Fahrmann, Edwin J. Ostrin, Kohei Yokoi, Toyofumi F. Chen-Yoshikawa, Yoshinori Hasegawa, Samir M. Hanash, Ignacio I. Wistuba, Ayumu Taguchi
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2331 (2024)
Early-stage lung adenocarcinoma (LUAD) patients remain at substantial risk for recurrence and disease-related death, highlighting the unmet need of biomarkers for the assessment and identification of those in an early stage who would likely benefit f
Externí odkaz:
https://doaj.org/article/3935571613464aff8604c12b722b1cf0
Autor:
Soei Gen, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Naozumi Hashimoto
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC
Externí odkaz:
https://doaj.org/article/0a13a5e26a90476f852a18912cc02403
Autor:
Takayuki Okuji, Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Masaaki Ito, Ayana Yamagami, Masahiko Ando, Tetsunari Hase, Hirofumi Shibata, Takahiro Hatta, Xin Zhou, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yuichi Ando, Naozumi Hashimoto
Publikováno v:
Nagoya Journal of Medical Science; Aug2024, Vol. 86 Issue 3, p452-463, 12p
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Yutaka Fujiwara, Reiko Makihara, Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito, Yukari Tsubata, Takae Okuno, Toshiaki Takahashi, Haruki Kobayashi, Yuki Shinno, Yoshitaka Zenke, Takaya Ikeda, Yukio Hosomi, Kageaki Watanabe, Satoru Kitazono, Naomi Sakiyama, Yoshinori Makino, Noboru Yamamoto
Publikováno v:
Cancer Science. 114:2087-2097
Autor:
Daisuke Onoshima, Tetsunari Hase, Naoto Kihara, Daiki Kuboyama, Hiromasa Tanaka, Naoya Ozawa, Hiroshi Yukawa, Mitsuo Sato, Kenji Ishikawa, Yoshinori Hasegawa, Makoto Ishii, Masaru Hori, Yoshinobu Baba
Publikováno v:
ACS Measurement Science Au. 3:113-119
Autor:
Takafumi Yamamoto, Hikaru Morooka, Takanori Ito, Masatoshi Ishigami, Kazuyuki Mizuno, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Kenji Yokota, Tetsunari Hase, Osamu Maeda, Naozumi Hashimoto, Yuichi Ando, Masashi Akiyama, Hiroki Kawashima
Publikováno v:
Journal of Gastroenterology and Hepatology. 38:251-258
Immune-related liver injury (liver-irAE) is a clinical problem with a potentially poor prognosis.We retrospectively collected clinical data from patients treated with immune checkpoint inhibitors between September 2014 and December 2021 at the Nagoya